UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549



                                    FORM 8-K



     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934



        Date of Report (Date of earliest event reported): August 19, 2011


                                 IMAGING3, INC.
             -----------------------------------------------------
             (Exact name of registrant as specified in its charter)



                                   CALIFORNIA
                ------------------------------------------------
                 (State or other jurisdiction of incorporation)


       000-50099                                        95-4451059
--------------------------                  ------------------------------------
 (Commission File Number)                   (I.R.S. Employer Identification No.)


                 3200 W. VALHALLA DR., BURBANK, CALIFORNIA 91505
        ---------------------------------------------------------------
               (Address of principal executive offices) (Zip Code)
       Registrant's telephone number, including area code: (818) 260-0930

NOT APPLICABLE
--------------------------------------------------------------------------------
(Former  name,  former  address and former  fiscal year,  if changed  since last
report)


Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions.

[_]  Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR240.14d-2(b))

[_]  Soliciting  material  pursuant  to  Rule  14a-12  under  Exchange  Act  (17
     CFR240.14a-12)

[_]  Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR240.14d-2(b))

[_]  Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR240.13e-4(c))





                                TABLE OF CONTENTS


SECTION 8.   OTHER EVENTS......................................................1

                        Item 8.01 Other Events.................................1

SECTION 9.   FINANCIAL STATEMENTS AND EXHIBITS ................................1

SIGNATURES.....................................................................2





SECTION 8. OTHER EVENTS

         Item 8.01.   Other Events.

         On August 19,  2011,  Imaging3,  Inc., a  California  corporation  (the
"Company")  conducted  an open  house  for  persons  to  come  to the  Company's
executive offices and observe a demonstration of the Company's  prototype of its
three dimensional medical diagnostic imaging device ( the "Device"), and to have
a question and answer  session  with  management.  In the  meeting,  the Company
disclosed that (1) it plans to resubmit its  application to the Federal Food and
Drug  Administration  (the "FDA") in 2011 after having a pre-filing meeting with
the agency reviewers, which the Company anticipates could occur within six weeks
of its request for such a meeting, (2) the Company plans to send a letter to the
FDA on or before  August 29, 2011  requesting  the  pre-filing  meeting with its
reviewers, and (3) the Company currently has engaged special consultants,  legal
counsel,  a radiologist and technical writers to assist management with the next
submission of its  application  to the FDA for the Device.  While  management is
confident that its  re-submission to the FDA will be ready for filing before the
end of 2011, and that the  pre-filing  meeting with FDA reviewers will occur and
will improve the  Company's  prospects  for eventual FDA approval of the Device,
there is no  assurance  that the FDA will grant the  Company's  request  for the
pre-submission  meeting  (although they have indicated a willingness to do so by
telephone), or that the FDA will ultimately approve the Device.

         In response to questions,  management disclosed that (1) the Company is
contemplating a finance deal with an institutional investor of its securities to
raise additional  capital to sustain its operations for the next eight to twelve
months,  from which there is  expected to be dilution to existing  stockholders,
(2) the  Company  is  seeking  two  independent  directors  to join its Board of
Directors, (3) management is not currently purchasing the Company's stock in the
open  market,  (4)  management  estimates  the  sale  price of each  machine  to
prospective  customers to be  approximately  $550,000  with an  estimated  gross
profit  margin of 50%, (5) the Company plans to attend trade shows with the same
displays as in the past, (6) if approved by the FDA, the Company plans to launch
its  marketing  campaign  with  the  stationing  of up to  twelve  demonstration
machines in selected sites,  and then ultimately work with a major  manufacturer
for production and  fulfillment of orders if orders are received by the Company,
(8) the FDA has not  seen the  machine  in  operation,  so  management  plans to
include a video  demonstration  of the Device in its next submission to the FDA,
(9) the Company does not plan to hire a public relations firm at this time, (10)
the  Company  does  not  currently  plan  to do a  reverse  stock  split  of its
outstanding  stock,  but may consider one in the future,  preferably near a time
when the Company  achieves a major  milestone,  (11) two prototype  Devices have
been built, one more is in production, and none are deployed in hospitals or yet
in commercial use, and (12) the re-submission to the FDA will include new images
and fresh data. In response to a question regarding the maintenance  schedule of
the machine during each  operating  cycle,  management  estimated a time span of
three to six months of operation between routine periodic maintenance, resulting
in  a  99%  overall   operational  rate.  The  Company  then  conducted  a  live
demonstration of the Device for those attendees interested to see it.


SECTION 9. FINANCIAL STATEMENTS, PRO FORMA FINANCIALS & EXHIBITS

         (a)      Financial Statements of Business Acquired

                  Not Applicable.


                                      -1-





         (b)      Pro Forma Financial Information

                  Not Applicable.

         (c)      Shell Company Transactions

                  Not Applicable.

         (d)      Exhibits

                  None.




                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended,
the  registrant  has duly  caused  this report to be signed on its behalf by the
undersigned, thereunto duly authorized.


                                 IMAGING3, INC.
                             -----------------------
                                  (Registrant)

Date:  August 19, 2011


                               /s/ Dean Janes, Chief Executive Officer
                               ---------------------------------------
                               Dean Janes, Chief Executive Officer




























                                      -2-